Business / Finance

RSS

Amgen acquires Bergamo, expands operations in Brazil

Amgen, the world's largest biotechnology company, announced today the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.

8 Apr 2011

Impax, Banner Pharmacaps collaborate for commercialization of softgel capsule products

Impax Laboratories, Inc. today announced that it will collaborate with Banner Pharmacaps Inc. with respect to the supply and commercialization of two softgel capsule products.

8 Apr 2011

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.

8 Apr 2011

Idenix begins underwritten registered public offering of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has commenced an underwritten registered public offering of shares of its common stock. All of these shares are being sold by Idenix.

8 Apr 2011

Catalyst Health prices public offering of 5,500,000 shares of common stock

Catalyst Health Solutions, Inc. today announced the successful pricing of its public offering of 5,500,000 shares of common stock, consisting of 4,500,000 shares to be sold by the Company and 1,000,000 shares to be sold by one of its stockholders, Principal Holding Company, LLC, a subsidiary of Principal Financial Group, Inc., at a price of $53.00 per share.

8 Apr 2011

Alcon to merge with Novartis at its Annual General Meeting of Shareholders

Alcon, Inc. announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders.

8 Apr 2011

Rochester Medical acquires Laprolan

Rochester Medical Corporation today announced that it has now completed the previously announced purchase of Laprolan B.V., the former Medical Supplies Division and wholly owned subsidiary of Fornix BioSciences N.V. Under the terms of the purchase agreement the purchase is deemed retroactive to January 1, 2011.

8 Apr 2011

Rite Aid reports fourth quarter net loss of $205.7 million

Rite Aid Corporation today reported financial results for the fourth quarter and fiscal year ended February 26, 2011.

7 Apr 2011

Gerresheimer first quarter group revenues increase 5.2% to EUR 236.6m

Gerresheimer AG, one of the leading global suppliers to the pharma and healthcare industry, got off to a good start in the new financial year. "We continued on our successful course in the new financial year.

7 Apr 2011

Alnylam defends against Tekmira complaint, files answer and counterclaim

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has filed an answer and counterclaim to a complaint filed by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court.

7 Apr 2011

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.

7 Apr 2011

LabCorp to acquire Orchid Cellmark

Laboratory Corporation of America® Holdings and Orchid Cellmark Inc., an international provider of DNA testing services primarily for forensic and family relationship applications, today announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Orchid Cellmark in a cash tender offer for $2.80 per share for a total purchase price to stockholders and optionholders of approximately $85.4 million.

6 Apr 2011

Ascletis raises $100 million in committed financing

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, today announced the company's formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States.

6 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Nu Skin first-quarter revenue increases 9% to $395 million

Nu Skin Enterprises, Inc. today announced that it expects to exceed previous company guidance by posting first-quarter revenue of approximately $395 million, a 9 percent improvement over the prior-year period. Revenue is expected to benefit approximately 5 percent due to foreign currency fluctuations.

6 Apr 2011

Viking expects record sales of $3.0 million for quarter ended March 31, 2011

Viking Systems, Inc., a leading worldwide developer, manufacturer and marketer of 3D and 2D visualization solutions for complex minimally invasive surgery, expects to report record sales for the quarter ended March 31, 2011 that will exceed $3.0 million, an increase of more than 50% compared with $1.9 million in revenue reported for last year's first quarter, and more than a 30% sequential increase over the fourth quarter of 2010.

6 Apr 2011

BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc., a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011.

6 Apr 2011

Sagent begins initial public offering of 5,000,000 shares of common stock

Sagent Pharmaceuticals, announced that it has commenced an initial public offering of 5,000,000 shares of common stock.

6 Apr 2011

MEDICREA reports €18.2 million annual sales for first quarter 2011

The MEDICREA Group listed on Alternext by NYSE Euronext Paris, a medical device company specialized in the development of innovative surgical technologies for the treatment of spinal disorders, is publishing its 2010 audited annual results approved by the Board of Directors held on March 31st, 2011, and its 2011 first quarter sales.

6 Apr 2011

GenVec announces one for ten reverse stock split

Today GenVec, Inc. announced that it will implement a one for ten reverse stock split of the Company's outstanding shares of common stock. The reverse stock split will be effective with respect to stockholders of record at the close of business on Monday, April 18, 2011, and trading of the Company's common stock on the NASDAQ Capital Market will begin on a split-adjusted basis at the opening of trading on Tuesday, April 19, 2011.

6 Apr 2011